Last reviewed · How we verify

NCT04653857: CADE

Cardiac Assessment After Covid-19 Disease in Elite Altheltic Population

Status unknown Last updated 7 December 2020
What this trial tests

trial in Covid19 in 250 participants. Status unknown.

Timeline
1 April 2020
Primary endpoint
30 April 2020
1 January 2021

Quick facts

Lead sponsorUniversity Hospital, Montpellier
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment250
Start date1 April 2020
Primary completion30 April 2020
Estimated completion1 January 2021
Sites1 location across France

Conditions studied

Sponsor

University Hospital, Montpellier

Who can join

Adults 10 to 50, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

COVID-19 infection coud induce cardiac injuries. Before returning to sport, cardiac evaluation is recommended by sports federations, based on the precautionary principle and the opinion of expert consensus. The aim of this study is to to determine the prevalence of abnormalities in cardiological examinations realized in athletes who have suffered from COVID-19 infection, symptomatic or not.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

Other University Hospital, Montpellier trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04653857.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing